Day One Biopharmaceuticals recently received FDA approval for its first drug and is now building its pipeline with a deal to acquire rights to a novel drug from MabCare Therapeutics, originally named DAY301. This drug targets protein-tyrosine kinase 7 (PTK7) found in certain cancer cells. Other companies, like Genmab, are also developing PTK7-targeting drugs. Day One’s business model involves securing rights to drug candidates developed by other companies, with Ojemda being its first approved drug. The company is well-funded and has plans to expand its pipeline. The Phase 1 study for DAY301 is expected to begin soon.
Source link
Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug
